Status:
COMPLETED
Impact of Insulin on Sympathetic Nervous System-mediated Peripheral Vasoconstriction
Lead Sponsor:
University of Missouri-Columbia
Conditions:
Vasoconstriction
Healthy
Eligibility:
All Genders
18-45 years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this project is to determine if hyperinsulinemia attenuates sympathetic nervous system-mediated vasoconstriction in the human leg.
Eligibility Criteria
Inclusion
- healthy adult men and women;
- 18-45 years of age;
- BMI 18-30 kg/m2;
- non-pregnant/non-breastfeeding;
- non-nicotine users;
Exclusion
- taking any medications known to affect metabolic, respiratory, cardiovascular, and/or autonomic functions
- Self-reported history of:
- hepatic, renal, pulmonary, cardiovascular, or neurological disease;
- stroke or neurovascular disease;
- bleeding/clotting disorders;
- sleep apnea or other sleep disorders;
- diabetes;
- smoking;
- history of alcoholism or substance abuse, excessive alcohol consumption;
- hypertension;
- active cancer;
- autoimmune disease;
- immunosuppressant therapy
Key Trial Info
Start Date :
August 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 25 2021
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT05244694
Start Date
August 6 2020
End Date
June 25 2021
Last Update
February 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Missouri
Columbia, Missouri, United States, 65211